Referenser

  1. Spedra produktresumé april 2018.
  2. Wang R et al. Selectivity of avanafil, a PDE5 inhibitor for the treatment of erectile dysfunction: Implications for clinical safety and improved tolerability.
  3. Corona G et al. The safety and efficacy of Avanafil, a new 2 nd generation PDE5i: comprehensive review and meta-analysis, Expert Opinion on Drug Safety, 15(2), 237–47.
  4. Goldstein I et al. A randomized, double-blind, placebo-controlled Evaluation of the safety and efficacy of avanafil in subjects with erectile dysfunction. J Sex Med 2012;9:1122–1133.
  5. Jiann et al. Compliance of sildenafil treatment for erectile dysfunction and factors affecting it. Int J Impot Res, (2006) 18, 146-149.
  6. Carvalheira AA et al. Dropout in the treatment of erectile dysfunction with PDE5: A study on predictors and a qualitative analysis of reasons for discontinuation. J Sex Med 2012;9:2361–2369.
  7. Ljunggren C, Hedelin H, Salomonsson K, and Ströberg P. Giving patients with erectile dysfunction the opportunity to try all  three available phosphodiesterase type 5 inhibitors contributes to better long-term treatment compliance. J Sex Med. 2008 Feb;5(2):469-75. Epub 2007 Dec 13.
  8. Hatzimouratidis K et al. EAU Guidelines on Male Sexual Dysfunction: Erectile dysfunction and premature ejaculation. www.uroweb.org/guidelines 
  9. Goldstein I et al. Avanafil for the treatment of erectile dysfunction: A multicenter, randomized, double-blind study in men with diabetes mellitus, Mayo Clin Proc. 2012;87(9):843-52.)
  10. Mulhall JP et al. A phase 3, placebo controlled study of the safety and efficacy of Avanafil for the treatment of erectile dysfunction after nerve sparing radical prostatectomy, J Urol. 2013;189(6):2229-36.
  11. Burri A and Porst H, Results from an online survey investigating ED patients’ insights and treatment expectations. Int J Impot Res (2015), 1-6.
  12. Hellstrom W et al. Efficacy of avanafil 15 minutes after dosing in men with erectile dysfunction: a randomized, double-blind, placebo-controlled study. J of Urol. 2015;Vol 194:485-492.
  13. Belkoff L H et al. An open.label, long-term evaluation of the safety, efficacy and tolerability of avanafil in male patients with mild to severe erectile dysfunction. Int J Clin Pract, April 2013,67,4,333-341.
  14. Chen L et al. Phosphodiesterase 5 inhibitors for the treatment of erectile dysfunction: A trade-off network meta-analysis. Eur Urol 2015, Mar 26.
  15. Della Camera P A et al. Urologia Journal 2020, Vol. 87 (1) 23-28. DOI: 10.1177/0391560319867809